Company Profile
Stoke Therapeutics Stock Price, News & Catalysts
- Ticker:
- STOK
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
32.29 USD (+2.83%)
Close
Last updated: August 21, 2026
1.79B USD
Market cap
Why the stock is moving
As of Aug 21, 2026, STOK closed up 2.83% at $32.29. No new same-company headline was identified in the current news window.
Company overview
Business overview
Stoke Therapeutics is a genetic-medicine company focused on RNA-based approaches for severe diseases such as epilepsy. Its platform is aimed at restoring protein expression in haploinsufficient conditions.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Stoke sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical proof, RNA platform validation, and the ability to translate genetic medicine into real value.
Position Within the Biotechnology Landscape
Stoke is a high-beta genetic-medicine name whose valuation is closely tied to clinical progress.
Future catalysts
- Stoke Therapeutics's catalysts are zorevunersen in Dravet syndrome and its SYNGAP1 program. The next update matters because the company’s neuroscience story is still very focused.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Stoke Therapeutics (STOK)?
Stoke Therapeutics (STOK) most recently closed at 32.29 USD, a +2.83% move versus the previous session.
What is the market cap of Stoke Therapeutics (STOK)?
Stoke Therapeutics currently has a market capitalization of 1.79B USD on BioPharmSignal.
What does Stoke Therapeutics do?
Stoke Therapeutics is a genetic-medicine company focused on RNA-based approaches for severe diseases such as epilepsy. Its platform is aimed at restoring protein expression in haploinsufficient conditions.
On which exchange is STOK stock listed?
Stoke Therapeutics (STOK) is associated with NASDAQ, United States, Biopharma.
What is Stoke?
Stoke Therapeutics's catalysts are zorevunersen in Dravet syndrome and its SYNGAP1 program.
Which conditions is Stoke Therapeutics targeting with Stoke?
Stoke Therapeutics is associated with neuroscience, genetic disease based on its company overview and current catalyst commentary.
How does Stoke Therapeutics describe recent progress with Stoke?
Stoke Therapeutics's catalysts are zorevunersen in Dravet syndrome and its SYNGAP1 program.
What is Therapeutics?
Stoke Therapeutics is a genetic-medicine company focused on RNA-based approaches for severe diseases such as epilepsy.